BLSM (BlossomHill Therapeutics) Other Financing: $0.59 Mil (TTM As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BLSM BlossomHill Therapeutics Inc BLSM
8 GF Score
Price $16.02
View Full Analysis

What is BlossomHill Therapeutics Other Financing?

BlossomHill Therapeutics BLSM -0.06% 8 Other Financing is $0.59 Mil as of Dec. 2025. GuruFocus rates BLSM with a GF Score™ of 8/100.

BlossomHill Therapeutics's Other Financing for the six months ended in Dec. 2025 was $0.59 Mil.

BlossomHill Therapeutics's Other Financing for the trailing twelve months (TTM) ended in Dec. 2025 was $0.59 Mil.

BlossomHill Therapeutics Other Financing Historical Data

* Premium members only.

The historical data trend for BlossomHill Therapeutics's Other Financing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BlossomHill Therapeutics Other Financing Chart

BlossomHill Therapeutics Annual Data
Trend Dec24 Dec25
Other Financing
0.42 0.59

BlossomHill Therapeutics Semi-Annual Data
Dec24 Dec25
Other Financing 0.42 0.59
BLSM
8GF Score
BlossomHill Therapeutics Inc BLSM
Other Financing is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

BlossomHill Therapeutics Other Financing Calculation

Other Financing represents other cash flow from financing activity that not otherwise classified, which includes:
Proceeds From Stock Option Exercised
Other Financing Charges

For stock reported annually, GuruFocus uses latest annual data as the TTM data. Other Financing for the trailing twelve months (TTM) ended in Dec. 2025 was $0.59 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Other Financing →
What does a Other Financing of $0.59 Mil mean?
BlossomHill Therapeutics (BLSM) has a Other Financing of $0.59 Mil as of Dec. 2025. Other Financing represents other cash flow from financing activity that not otherwise classified. View historical data for BlossomHill Therapeutics and its competitors.
Is BlossomHill Therapeutics' Other Financing too high?
BlossomHill Therapeutics' current Other Financing is $0.59 Mil. Overall, BlossomHill Therapeutics has a GF Score™ of 8/100, reflecting its overall financial health beyond just this single metric.
How does BlossomHill Therapeutics' Other Financing compare to ?
BlossomHill Therapeutics' Other Financing of $0.59 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Financing for a Biotechnology company?
A good Other Financing depends on the Biotechnology industry context. However, Other Financing should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Financing mean?
A high Other Financing can signal that a stock is expensive relative to its fundamentals. Other Financing represents other cash flow from financing activity that not otherwise classified. View historical data for BlossomHill Therapeutics and its competitors. BlossomHill Therapeutics's current Other Financing is $0.59 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BlossomHill Therapeutics stock overvalued right now?
BlossomHill Therapeutics (BLSM) has a current Other Financing of $0.59 Mil. The current Other Financing is $0.59 Mil. BlossomHill Therapeutics' overall GF Score™ is 8/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Financing calculated?
Other Financing is calculated from a company's financial statements. For BlossomHill Therapeutics (BLSM), the current Other Financing is $0.59 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

BlossomHill Therapeutics Business Description

Comparable Companies
Address 10255 Science Center Drive, Suite 200, San Diego, CA, USA, 92121
BlossomHill Therapeutics Inc is a clinical-stage biopharmaceutical company applying its intentional, chemistry-based approach to develop small molecule medicines that address unmet medical needs in cancer treatment. Its product pipeline includes two clinical-stage programs: BH-30643, an investigational, non-covalent, macrocyclic, brain active, mutant-selective OMNI-EGFR inhibitor for the treatment of epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC), and BH-30236, an investigational macrocyclic CDC-like kinase (CLK) inhibitor being evaluated first in relapsed or refractory acute myeloid leukemia (R/R AML) and higher-risk myelodysplastic syndromes (HR-MDS), and the preclinical-stage product candidate BH-501284 targeting activated KRAS.
8GF Score

Get the complete analysis for BLSM

Other Financing is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$16.02
Price